Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Non-Current Deffered Revenue (2016 - 2018)

Moleculin Biotech's Non-Current Deffered Revenue history spans 3 years, with the latest figure at $107000.0 for Q4 2018.

  • Quarterly results put Non-Current Deffered Revenue at $107000.0 for Q4 2018, down 28.67% from a year ago — trailing twelve months through Dec 2018 was $107000.0 (down 28.67% YoY), and the annual figure for FY2018 was $107000.0, down 28.67%.
  • Non-Current Deffered Revenue for Q4 2018 was $107000.0 at Moleculin Biotech, up from $92000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $150000.0 in Q2 2017 to a low of $12500.0 in Q2 2016.
  • The 3-year median for Non-Current Deffered Revenue is $125000.0 (2017), against an average of $113833.3.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 1100.0% in 2017, then crashed 38.67% in 2018.
  • Year by year, Non-Current Deffered Revenue stood at $88000.0 in 2016, then soared by 70.45% to $150000.0 in 2017, then decreased by 28.67% to $107000.0 in 2018.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $107000.0, $92000.0, and $150000.0 for Q4 2018, Q3 2018, and Q1 2018 respectively.